Pauline Lang

Ms. Pauline Lang

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 August 2019 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
AKAlen Krajnc
Alen Krajnc
JBJurgen Brem
Jurgen Brem
PHPhilip Hinchliffe
Philip Hinchliffe
KCKarina Calvopiña
Karina Calvopiña
TPTharindi D. Panduwawala
Tharindi D. Panduwawala
CSChristopher J. Schofield
Christopher J. Schofield
The bicyclic boronate VNRX-5133 is a new type of β-lactamase inhibitor in clinical development. We report that VNRX-5133 inhibits serine-β-lactamases (SBLs) and some clinically important metallo-β-lactamases (MBLs), including NDM-1 and VIM-1/2. VNRX-5133 activity against IMP-1 and tested B2/B3 MBLs was lower/not observed. Crystallography reveals how VNRX-5133 binds to the class D SBL OXA-10 and NDM-1. The crystallographic results highlight the ability of bicyclic boronates to inhibit SBLs and MBLs via binding of a tetrahedral (sp3) boron species. The structures imply conserved binding of the bicyclic core with SBLs/MBLs. With NDM-1, by crystallography we observed an unanticipated VNRX-5133 binding mode involving cyclization of its acylamino oxygen onto the boron of the bicyclic core. Different side-chain-dependent binding modes for bicyclic boronates imply scope for optimisation. The results further support the ‘high energy intermediate’ analogue approach for broad-spectrum β-lactamase inhibitor development and highlight the ability of boron-inhibitors to interchange between different hybridization states / binding modes.

1 June 2019 in Current Opinion in Chemical Biology
Verified
Journal Article
Open access
AKAlen Krajnc
Alen Krajnc
PLPauline Lang
Pauline Lang
TPTharindi Panduwawala
Tharindi Panduwawala
JBJurgen Brem
Jurgen Brem
CSChristopher J. Schofield
Christopher J. Schofield
The β-lactams remain the most important antibacterials, but their use is increasingly compromised by resistance, importantly by β-lactamases. Although β-lactam and non-β-lactam inhibitors forming stable acyl-enzyme complexes with nucleophilic serine β-lactamases (SBLs) are widely used, these are increasingly susceptible to evolved SBLs and do not inhibit metallo-β-lactamases (MBLs). Boronic acids and boronate esters, especially cyclic ones, can potently inhibit both SBLs and MBLs. Vaborbactam, a monocyclic boronate, is approved for clinical use, but its β-lactamase coverage is limited. Bicyclic boronates rapidly react with SBLs and MBLs forming stable enzyme-inhibitor complexes that mimic the common anionic high-energy tetrahedral intermediates in SBL/MBL catalysis, as revealed by crystallography. The ability of boronic acids to 'morph' between sp2 and sp3 hybridisation states may help enable potent inhibition. There is limited structure-activity relationship information on the (bi)cyclic boronate inhibitors compared to β-lactams, hence scope for creativity towards new boron-based β-lactamase inhibitors/antibacterials.

13 December 2021 in Nature Chemistry
Verified
Journal Article
Closed access
PDF file
JBJurgen Brem
Jurgen Brem
TPTharindi Panduwawala
Tharindi Panduwawala
JHJon Ulf Hansen
Jon Ulf Hansen
JHJoanne Hewitt
Joanne Hewitt
ELEdgars Liepins
Edgars Liepins
CSChristopher J. Schofield
Christopher J. Schofield

1 October 2019 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
CTCatherine L. Tooke
Catherine L. Tooke
PHPhilip Hinchliffe
Philip Hinchliffe
PLPauline Lang
Pauline Lang
AMAdrian J. Mulholland
Adrian J. Mulholland
JBJurgen Brem
Jurgen Brem
JSJames Spencer
James Spencer
β-Lactamase production is the major β-lactam resistance mechanism in Gram-negative bacteria. β-Lactamase inhibitors (BLIs) efficacious against serine β-lactamase (SBL) producers, especially strains carrying the widely disseminated class A enzymes, are required. Relebactam, a diazabicyclooctane (DBO) BLI, is in phase 3 clinical trials in combination with imipenem for the treatment of infections by multidrug-resistant Enterobacteriaceae. We show that relebactam inhibits five clinically important class A SBLs (despite their differing spectra of activity), representing both chromosomal and plasmid-borne enzymes, i.e., the extended-spectrum β-lactamases L2 (inhibition constant 3 μM) and CTX-M-15 (21 μM) and the carbapenemases KPC-2, -3, and -4 (1 to 5 μM). Against purified class A SBLs, relebactam is an inferior inhibitor compared with the clinically approved DBO avibactam (9- to 120-fold differences in half maximal inhibitory concentration [IC50]). MIC assays indicate relebactam potentiates β-lactam (imipenem) activity against KPC-producing Klebsiella pneumoniae, with similar potency to avibactam (with ceftazidime). Relebactam is less effective than avibactam in combination with aztreonam against Stenotrophomonas maltophilia K279a. X-ray crystal structures of relebactam bound to CTX-M-15, L2, KPC-2, KPC-3, and KPC-4 reveal its C2-linked piperidine ring can sterically clash with Asn104 (CTX-M-15) or His/Trp105 (L2 and KPCs), rationalizing its poorer inhibition activity than that of avibactam, which has a smaller C2 carboxyamide group. Mass spectrometry and crystallographic data show slow, pH-dependent relebactam desulfation by KPC-2, -3, and -4. This comprehensive comparison of relebactam binding across five clinically important class A SBLs will inform the design of future DBOs, with the aim of improving clinical efficacy of BLI–β-lactam combinations.

22 July 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
ABAgata Butryn
Agata Butryn
PSPhilipp S. Simon
Philipp S. Simon
PAPierre Aller
Pierre Aller
PHPhilip Hinchliffe
Philip Hinchliffe
RMRamzi N. Massad
Ramzi N. Massad
AOAllen M. Orville
Allen M. Orville
Serial femtosecond crystallography has opened up many new opportunities in structural biology. In recent years, several approaches employing light-inducible systems have emerged to enable time-resolved experiments that reveal protein dynamics at high atomic and temporal resolutions. However, very few enzymes are light-dependent, whereas macromolecules requiring ligand diffusion into an active site are ubiquitous. In this work we present a drop-on-drop sample delivery system that enables the study of enzyme-catalyzed reactions in microcrystal slurries. The system delivers ligand solutions in bursts of multiple picoliter-sized drops on top of a larger crystal-containing drop inducing turbulent mixing and transports the mixture to the X-ray interaction region with temporal resolution. We demonstrate mixing using fluorescent dyes, numerical simulations and time-resolved serial femtosecond crystallography, which show rapid ligand diffusion through microdroplets. The drop-on-drop method has the potential to be widely applicable to serial crystallography studies, particularly of enzyme reactions with small molecule substrates.

20 August 2021 in Science Advances
Verified
Journal Article
Open access
PRPatrick Rabe
Patrick Rabe
JKJos J. A. G. Kamps
Jos J. A. G. Kamps
KSKyle D. Sutherlin
Kyle D. Sutherlin
JLJames D. S. Linyard
James D. S. Linyard
PAPierre Aller
Pierre Aller
CSChristopher J. Schofield
Christopher J. Schofield
Complementary XFEL methods reveal O 2 reaction intermediates and global protein dynamics during Isopenicillin N synthase catalysis.